<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454142</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00197</org_study_id>
    <secondary_id>NCI-2009-00197</secondary_id>
    <secondary_id>CDR0000537520</secondary_id>
    <secondary_id>CTRG-NP05/25/06</secondary_id>
    <secondary_id>NCC-06-01</secondary_id>
    <secondary_id>7623</secondary_id>
    <nct_id>NCT00454142</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer</brief_title>
  <official_title>A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well pazopanib hydrochloride works in&#xD;
      treating patients with stage IV or recurrent nasopharyngeal cancer. Pazopanib hydrochloride&#xD;
      may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and&#xD;
      by blocking blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of pazopanib hydrochloride in patients with stage IV or recurrent&#xD;
      nasopharyngeal carcinoma.&#xD;
&#xD;
      II. Determine the progression-free survival of patients treated with this drug. III.&#xD;
      Determine the toxicity of this drug in these patients. IV. Determine the effect of this drug&#xD;
      on angiogenesis inhibition using dynamic contrast-enhanced computed tomography (CT) scan.&#xD;
&#xD;
      V. Determine the pharmacokinetic profile of this drug in these patients. VI. Correlate the&#xD;
      effect of this drug on angiogenesis inhibition with the clinical benefit rate and&#xD;
      pharmacokinetics.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-21. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for up to 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Clinical benefit rate (CBR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST ver 1.0) and assessed by CT or MRI. CBR includes 1) Complete response (CR): disappearance of all lesions; 2) partial response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions and 3) stable disease (SD): non-PR and non progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (PR)</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Per response evaluation criteria in solid tumors (RECIST v1.0) and assessed by MRI or CT: Partial response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions and non-PD (PD: progressive disease) of non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From the date of enrollment to the date of first documented progression or death, whichever occurs first, or to the date when the patient was last known to be alive, up to 3 years.</time_frame>
    <description>Progression will be evaluated in this study using the new international criteria proposed by RECIST Committee. The sample proportion and associated 95% confidence interval will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of enrollment to the study to the date of death from any cause or to the date when the patient was last known to be alive, up to 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile: Percentage of Participants With Significant (Grade 3/4) Related Adverse Event (AE)</measure>
    <time_frame>From the time of first treatment with pazopanib hydrochloride to up to 30days after completion of treatment</time_frame>
    <description>The frequencies of grade 3/4 related toxicities were recorded among all participants, and the percentage of participants who experienced significant AEs were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Study: Tumor Blood Flow at Baseline</measure>
    <time_frame>Pretreatment</time_frame>
    <description>Dynamic-contrast enhanced computed tomography (DCE-CT) was performed at baseline and Day 28, tumor blood flow was measured.19 of 33 patients had evaluable DCE-CT data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Study: Tumor Blood Flow on Day 28</measure>
    <time_frame>28 days post treatment</time_frame>
    <description>DCE-CT was performed on Day 28 and tumor blood flow was measured. 19 of 33 patients had evaluable DCE-CT data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study: Percentage of Participants With Trough Concentration at Steady State (Day 28) Above 15 Âµg/mL</measure>
    <time_frame>Day 28 of treatment</time_frame>
    <description>Pazopanib pharmacokinetic parameters were estimated on Day 1 and Day 28 (steady state). Trough concentration of pazopanib was measured on Day 28 with blood sampling at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after Day 28 dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study: AUC0-24h/Dose on Day 1</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>AUC 0-24h/dose were measured on day 1 for 26 evaluable participants. Blood sampling is done at zero (pre-dose), 0.5 hr, 1, 2, 3, 4, 5, 6 and 8 hrs after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study: Area Under Curve (AUC) 0-24h/Dose on Day 28</measure>
    <time_frame>Day 28 of treatment</time_frame>
    <description>AUC 0-24h/dose were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study: Volume of Distribution (Vd/F/Dose) on Day 1</measure>
    <time_frame>Day 1 of treatment</time_frame>
    <description>Volume of distribution (Vd/F/dose) were measured on day 1 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 hrs after first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Study: Volume of Distribution at Steady State (Vss/F/Dose) on Day 28</measure>
    <time_frame>Day 28 of treatment</time_frame>
    <description>Volume of distribution at steady state (Vss/F/Dose) were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Recurrent Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <arm_group>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <other_name>GW786034B</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed nasopharyngeal carcinoma, meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  World Health Organization (WHO) type II-III disease&#xD;
&#xD;
               -  Stage IV or recurrent disease&#xD;
&#xD;
          -  Must have failed at least 1 prior line of chemotherapy for metastatic or recurrent&#xD;
             disease&#xD;
&#xD;
          -  Measurable disease, defined as &gt;= 1 unidimensionally measurable lesion &gt;= 20 mm by&#xD;
             conventional techniques OR &gt;= 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 or Karnofsky PS&#xD;
             70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WBC &gt;= 3,000/mmÂ³&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mmÂ³&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mmÂ³&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 times upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Proteinuria =&lt; 1+ on 2 consecutive dipsticks taken &gt;= 1 week apart&#xD;
&#xD;
          -  Prothrombin time (PT), international normalized ratio (INR), and partial&#xD;
             thromboplastin time (PTT) =&lt; 1.2 times ULN&#xD;
&#xD;
          -  Systolic blood pressure (BP) =&lt; 140 mm Hg and diastolic BP =&lt; 90 mm Hg&#xD;
&#xD;
               -  Initiation or adjustment of BP medication allowed provided the average of 3 BP&#xD;
                  readings are &lt; 140/90 mm Hg prior to study entry&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to pazopanib hydrochloride or to other study agents&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 28 days&#xD;
&#xD;
          -  No cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  No history of any of the following diseases within the past 12 weeks:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Admission for unstable angina&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Venous thrombosis&#xD;
&#xD;
          -  No New York Heart Association (NYHA) class III-IV heart failure&#xD;
&#xD;
               -  Patients with a history of NYHA class II heart failure are eligible provided they&#xD;
                  are asymptomatic on treatment&#xD;
&#xD;
          -  No significant electrocardiogram (ECG) abnormalities, including QTc prolongation&#xD;
             (i.e., QTc &gt;= 500 msec)&#xD;
&#xD;
          -  No serious or non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No condition that would impair the ability to swallow and retain pazopanib&#xD;
             hydrochloride, including any of the following:&#xD;
&#xD;
               -  Gastrointestinal tract disease resulting in an inability to take oral medication&#xD;
&#xD;
               -  Requirement for IV alimentation&#xD;
&#xD;
               -  Prior surgical procedures affecting absorption&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, the following:&#xD;
&#xD;
               -  Coagulopathy&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No known allergy to CT contrast agents&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
             and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
          -  No prior antiangiogenesis therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent medications or substances known to affect or with the potential to&#xD;
             affect the activity or pharmacokinetics of pazopanib hydrochloride, as determined by&#xD;
             the Principal Investigator&#xD;
&#xD;
          -  No concurrent medications that have the potential to interact with the cytochrome P450&#xD;
             (CYP) isoenzymes CYP2C9 and CYP3A4&#xD;
&#xD;
          -  No concurrent therapeutic warfarin&#xD;
&#xD;
               -  Low molecular weight heparin or prophylactic low-dose warfarin allowed&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for human immunodeficiency virus (HIV)-positive&#xD;
             patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan Teck Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapeutics Research Group</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>November 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2015</results_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled from 2 sites in Singapore, 27 were enrolled from National Cancer Centre Singapore and 6 were enrolled from National University Hospital.</recruitment_details>
      <pre_assignment_details>Once a subject signed the informed consent form, the required screening procedures would be performed.Eligible subjects would undergo 2 times of DCE-CT scan before study drug administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Tyrosine Kinase Inhibitor)</title>
          <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Tyrosine Kinase Inhibitor)</title>
          <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (PR)</title>
        <description>Per response evaluation criteria in solid tumors (RECIST v1.0) and assessed by MRI or CT: Partial response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions and non-PD (PD: progressive disease) of non-target lesions.</description>
        <time_frame>12 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (PR)</title>
          <description>Per response evaluation criteria in solid tumors (RECIST v1.0) and assessed by MRI or CT: Partial response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions and non-PD (PD: progressive disease) of non-target lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression will be evaluated in this study using the new international criteria proposed by RECIST Committee. The sample proportion and associated 95% confidence interval will be reported.</description>
        <time_frame>From the date of enrollment to the date of first documented progression or death, whichever occurs first, or to the date when the patient was last known to be alive, up to 3 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Tyrosine Kinase Inhibitor)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression will be evaluated in this study using the new international criteria proposed by RECIST Committee. The sample proportion and associated 95% confidence interval will be reported.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.9" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate</title>
        <description>Clinical benefit rate (CBR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST ver 1.0) and assessed by CT or MRI. CBR includes 1) Complete response (CR): disappearance of all lesions; 2) partial response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions and 3) stable disease (SD): non-PR and non progressive disease.</description>
        <time_frame>12 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Tyrosine Kinase Inhibitor)</title>
            <description>Patients receive pazopanib hydrochloride PO daily (QD) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>Clinical benefit rate (CBR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST ver 1.0) and assessed by CT or MRI. CBR includes 1) Complete response (CR): disappearance of all lesions; 2) partial response (PR): &gt;=30% decrease in the sum of the longest diameter of target lesions and 3) stable disease (SD): non-PR and non progressive disease.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="38.0" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From date of enrollment to the study to the date of death from any cause or to the date when the patient was last known to be alive, up to 3 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="8.6" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile: Percentage of Participants With Significant (Grade 3/4) Related Adverse Event (AE)</title>
        <description>The frequencies of grade 3/4 related toxicities were recorded among all participants, and the percentage of participants who experienced significant AEs were reported.</description>
        <time_frame>From the time of first treatment with pazopanib hydrochloride to up to 30days after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Tyrosine Kinase Inhibitor)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile: Percentage of Participants With Significant (Grade 3/4) Related Adverse Event (AE)</title>
          <description>The frequencies of grade 3/4 related toxicities were recorded among all participants, and the percentage of participants who experienced significant AEs were reported.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Study: Tumor Blood Flow at Baseline</title>
        <description>Dynamic-contrast enhanced computed tomography (DCE-CT) was performed at baseline and Day 28, tumor blood flow was measured.19 of 33 patients had evaluable DCE-CT data.</description>
        <time_frame>Pretreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Study: Tumor Blood Flow at Baseline</title>
          <description>Dynamic-contrast enhanced computed tomography (DCE-CT) was performed at baseline and Day 28, tumor blood flow was measured.19 of 33 patients had evaluable DCE-CT data.</description>
          <units>ml/100ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Study: Tumor Blood Flow on Day 28</title>
        <description>DCE-CT was performed on Day 28 and tumor blood flow was measured. 19 of 33 patients had evaluable DCE-CT data.</description>
        <time_frame>28 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Study: Tumor Blood Flow on Day 28</title>
          <description>DCE-CT was performed on Day 28 and tumor blood flow was measured. 19 of 33 patients had evaluable DCE-CT data.</description>
          <units>ml/100ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Study: Percentage of Participants With Trough Concentration at Steady State (Day 28) Above 15 Âµg/mL</title>
        <description>Pazopanib pharmacokinetic parameters were estimated on Day 1 and Day 28 (steady state). Trough concentration of pazopanib was measured on Day 28 with blood sampling at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after Day 28 dose.</description>
        <time_frame>Day 28 of treatment</time_frame>
        <population>Patients (total 26) with both Day 1 and Day 28 pharmacokinetic parameters were included.The trough concentration of pazopanib on Day 28 was observed to be above 15ug/ml in approximately 92% of patients at steady state.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Study: Percentage of Participants With Trough Concentration at Steady State (Day 28) Above 15 Âµg/mL</title>
          <description>Pazopanib pharmacokinetic parameters were estimated on Day 1 and Day 28 (steady state). Trough concentration of pazopanib was measured on Day 28 with blood sampling at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after Day 28 dose.</description>
          <population>Patients (total 26) with both Day 1 and Day 28 pharmacokinetic parameters were included.The trough concentration of pazopanib on Day 28 was observed to be above 15ug/ml in approximately 92% of patients at steady state.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Study: AUC0-24h/Dose on Day 1</title>
        <description>AUC 0-24h/dose were measured on day 1 for 26 evaluable participants. Blood sampling is done at zero (pre-dose), 0.5 hr, 1, 2, 3, 4, 5, 6 and 8 hrs after the first dose.</description>
        <time_frame>Day 1 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Study: AUC0-24h/Dose on Day 1</title>
          <description>AUC 0-24h/dose were measured on day 1 for 26 evaluable participants. Blood sampling is done at zero (pre-dose), 0.5 hr, 1, 2, 3, 4, 5, 6 and 8 hrs after the first dose.</description>
          <units>hr*ng/mL/mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="836.23" lower_limit="165.73" upper_limit="1869.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Study: Area Under Curve (AUC) 0-24h/Dose on Day 28</title>
        <description>AUC 0-24h/dose were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
        <time_frame>Day 28 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Study: Area Under Curve (AUC) 0-24h/Dose on Day 28</title>
          <description>AUC 0-24h/dose were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
          <units>hr*ng/mL/mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1192.35" lower_limit="82.96" upper_limit="4345.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Study: Volume of Distribution (Vd/F/Dose) on Day 1</title>
        <description>Volume of distribution (Vd/F/dose) were measured on day 1 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 hrs after first dose.</description>
        <time_frame>Day 1 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Study: Volume of Distribution (Vd/F/Dose) on Day 1</title>
          <description>Volume of distribution (Vd/F/dose) were measured on day 1 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 hrs after first dose.</description>
          <units>mL/mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.09" lower_limit="8.34" upper_limit="79.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Study: Volume of Distribution at Steady State (Vss/F/Dose) on Day 28</title>
        <description>Volume of distribution at steady state (Vss/F/Dose) were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
        <time_frame>Day 28 of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
pazopanib hydrochloride: Given PO&#xD;
pharmacological study: Correlative studies&#xD;
computed tomography: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Study: Volume of Distribution at Steady State (Vss/F/Dose) on Day 28</title>
          <description>Volume of distribution at steady state (Vss/F/Dose) were measured on day 28 for 26 evaluable participants. Blood sampling was done at zero (pre dose), 0.5 hr, 1, 2, 3, 4, 5, 6, 8 and 24 hrs after day 28 dose.</description>
          <units>mL/mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.23" lower_limit="16.58" upper_limit="1601.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of first treatment with pazopanib hydrochloride to up to 1 month after completion of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Tyrosine Kinase Inhibitor)</title>
          <description>Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
computed tomography : Correlative studies&#xD;
pharmacological study : Correlative studies&#xD;
pazopanib hydrochloride : Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot-skin reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wan Teck LIM</name_or_title>
      <organization>National Cancer Centre Singapore</organization>
      <phone>65-64368174</phone>
      <email>dmolwt@nccs.com.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

